register

News & Trends - MedTech & Diagnostics

Immunexpress to revolutionise sepsis diagnosis

Health Industry Hub | November 16, 2020 |

MedTech News: Immunexpress, a Brisbane based molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced the receipt of a Growth Grant to support the commercialisation of SeptiCyte RAPID in Australia.

The Growth Grant was secured through the Entrepreneurs’ Programme, a $400 million government initiative to help small businesses become more competitive and to accelerate their growth.

The funds have been used to install the Biocartis Idylla platform at the University of Queensland, and to train technicians on SeptiCyte RAPID.

“The receipt of this grant and our inclusion in the Entrepreneurs’ Programme reinforces Immunexpress’ commitment to the Australian community,” stated Rolland D. Carlson, Ph.D., Chief Executive Officer of Immunexpress. 

You may also like Successful leaders are ‘one of us’, according to UQ research

“The support provided by the Programme will enable us to accelerate the commercialisation of SeptiCyte RAPID in Australia. We plan to register SeptiCyte RAPID with the Australian Therapeutic Goods Administration (TGA) later this year, enabling us to provide Australian healthcare providers with SeptiCyte RAPID.

“SeptiCyte RAPID, a host response test to promptly rule in or rule out sepsis, has the potential to make an important impact on the healthcare community through improving patient outcomes by allowing for earlier diagnosis and appropriate antimicrobial treatment within a clinically relevant time,” he stated.

SeptiCyte RAPID addresses an important unmet medical need within the healthcare system in Australia by revolutionising sepsis diagnosis and providing actionable results to clinicians in an hour. SeptiCyte RAPID can determine the likelihood of sepsis and differentiate from non-infectious systemic inflammatory response syndrome (SIRS) in critically ill patients. 

Patrick Harris, Ph.D., Acting Statewide Director of Microbiology at Pathology Queensland, stated, “we are looking forward to exploring new avenues in rapid diagnostics by measuring genetic signatures in the host response to sepsis. Combined with rapid pathogen detection, SeptiCyte RAPID could prove to be a very powerful tool.”

Sepsis is a life-threatening generalised inflammation caused by the immune system’s response to an infection. 

About SeptiCyte RAPID

SeptiCyte RAPID is a gene expression assay discovered and patented from Australia, which uses reverse transcription polymerase chain reaction (PCR) to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene Blood RNA Tube. SeptiCyte RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis. SeptiCyte RAPID generates a score (SeptiScore) that falls within one of three discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. SeptiCyte RAPID is intended for in-vitro diagnostic use and is used on the Biocartis Idylla System.

In March 2020, Immunexpress received CE Marking of SeptiCyte RAPID and announced a long-term commercialization partnership with Biocartis in Europe. 


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.